Carcinoma in situ i mammae

Marica Skaar; Linnea Langhans; Birgitte Mertz; Niels Kroman

Carcinoma in situ i mammae

Translated title of the contribution: Ductal carcinoma in situ

Marica Skaar, Linnea Langhans, Birgitte Mertz, Niels Kroman

Department of Clinical Medicine

Abstract

Ductal carcinoma in situ (DCIS) is a premalignant lesion in the breast. It is often asymptomatic and diagnosed by screening mammography. DCIS is treated in line with low-risk invasive breast cancer including mastectomy or breast-conserving treatment plus radiotherapy, implicating a risk of both physical and psychological side effects. Since only a part of DCIS lesions develop into invasive cancer, some women suffer from overtreatment. However, it remains yet to be identified, in which subgroup of women with DCIS treatment can safely be omitted. We need to know more about the natural course of DCIS and develop tools to tailor treatment individually.

Translated title of the contribution	Ductal carcinoma in situ
Original language	Danish
Article number	V01170084
Journal	Ugeskrift for Laeger
Volume	180
Issue number	38
Number of pages	4
ISSN	0041-5782
Publication status	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

http://ugeskriftet.dk/videnskab/carcinoma-situ-i-mammae

Cite this

@article{8294106152d74af0a22612a47bb108e9,

title = "Carcinoma in situ i mammae",

abstract = "Ductal carcinoma in situ (DCIS) is a premalignant lesion in the breast. It is often asymptomatic and diagnosed by screening mammography. DCIS is treated in line with low-risk invasive breast cancer including mastectomy or breast-conserving treatment plus radiotherapy, implicating a risk of both physical and psychological side effects. Since only a part of DCIS lesions develop into invasive cancer, some women suffer from overtreatment. However, it remains yet to be identified, in which subgroup of women with DCIS treatment can safely be omitted. We need to know more about the natural course of DCIS and develop tools to tailor treatment individually.",

author = "Marica Skaar and Linnea Langhans and Birgitte Mertz and Niels Kroman",

year = "2018",

language = "Dansk",

volume = "180",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "38",

}

TY - JOUR

T1 - Carcinoma in situ i mammae

AU - Skaar, Marica

AU - Langhans, Linnea

AU - Mertz, Birgitte

AU - Kroman, Niels

PY - 2018

Y1 - 2018

N2 - Ductal carcinoma in situ (DCIS) is a premalignant lesion in the breast. It is often asymptomatic and diagnosed by screening mammography. DCIS is treated in line with low-risk invasive breast cancer including mastectomy or breast-conserving treatment plus radiotherapy, implicating a risk of both physical and psychological side effects. Since only a part of DCIS lesions develop into invasive cancer, some women suffer from overtreatment. However, it remains yet to be identified, in which subgroup of women with DCIS treatment can safely be omitted. We need to know more about the natural course of DCIS and develop tools to tailor treatment individually.

AB - Ductal carcinoma in situ (DCIS) is a premalignant lesion in the breast. It is often asymptomatic and diagnosed by screening mammography. DCIS is treated in line with low-risk invasive breast cancer including mastectomy or breast-conserving treatment plus radiotherapy, implicating a risk of both physical and psychological side effects. Since only a part of DCIS lesions develop into invasive cancer, some women suffer from overtreatment. However, it remains yet to be identified, in which subgroup of women with DCIS treatment can safely be omitted. We need to know more about the natural course of DCIS and develop tools to tailor treatment individually.

M3 - Tidsskriftartikel

C2 - 30259839

SN - 0041-5782

VL - 180

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 38

M1 - V01170084

ER -

Carcinoma in situ i mammae

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this